Dow Review: Johnson & Johnson
The following video is part of our "Motley Fool Conversations" series, in which analyst John Reeves and advisor David Meier discuss topics from across the investing world.
Over the next couple of weeks, John and David will be revisiting some calls they made on individual stocks of the Dow. Today, they're looking at Johnson & Johnson. Earlier this year, John and David believed this company would outperform the market over the next five years. And so far in 2012, this company is up a solid 5% compared to a similar gain for the Dow average as a whole. And let's not forget that Johnson & Johnson pays a pretty attractive dividend , too. Ironically, the company entered 2012 as one of the Dogs of the Dow along with fellow pharma giants Merck and Pfizer. And even with the recent rise in its share price, it still pays a 3.6% dividend yield. John and David are still confident that Johnson & Johnson will outperform the market over the next five years. Not only is it a great company, but its new CEO, Alex Gorsky, looks to bring some renewed energy to the firm.
Johnson & Johnson offers up a very attractive dividend yield. If you're interested in learning about some additional, outstanding high-yielding companies, The Motley Fool has compiled a special free report outlining our top nine dependable, dividend-paying stocks. It's called "Secure Your Future With 9 Rock-Solid Dividend Stocks." You can access your copy today at no cost! Just click here to discover the winners we've picked.
The article Dow Review: Johnson & Johnson originally appeared on Fool.com.David Meierhas no positions in the stocks mentioned above.John Reeveshas no positions in the stocks mentioned above. The Motley Fool owns shares of Abbott Laboratories and Johnson & Johnson.Motley Fool newsletter services recommendJohnson & Johnson and Pfizer. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.